Trade Mark Journal No.2026/042 16 October 2026

WO0000001940880 (5,10,42)

Office of origin: United States of America

Date of International Registration:22 July 2026
Date of designation in the UK: 22 July 2026
Image for mark 1940880

The mark consists of the stylized lowercase wording "BEREN", where the letters "BE" are connected by a horizontal infinity symbol.

International priority date claimed: 3 February 2026 (United States of America) (99630926)
Class 5
Pharmaceutical preparations for the prevention and treatment of a variety of ailments and conditions, namely, acute bronchitis, allergies, arthritis, asthma, cancer, cellulitis, cirrhosis, common cold, cold sore, conjunctivitis, cystitis, diabetes, diarrhea, ear infection, fever, fibromyalgia, fungal infection, gastroenteritis, headaches, hemorrhoids, high cholesterol, hyperglycemia, hypoglycemia, indigestion, irritable bowel syndrome, influenza, laryngitis, lyme disease, meningitis, mononucleosis, osteoporosis, pneumonia, pyelonephritis, rosacea, sinusitis, skin abscess, stomach aches, and streptococcal pharyngitis.
Class 10
Medical devices for the purposes of lowering cholesterol.
Class 42
Research and development of new products, pharmaceutical preparations, and medical devices; scientific, medical, and pharmaceutical research and development; medical research and development in the field of medicine, medical devices, and pharmaceuticals; drug discovery services; providing medical and scientific research information in the field of medicine, medical devices, and pharmaceuticals; scientific investigations for medical purposes; conducting research and clinical trials for others in the field of medicine, medical devices, and pharmaceuticals.

Beren GmbH

Representative: Ben Natter Haug Partners, LLP, 745 Fifth Avenue, New York NY 10151, UNITED STATES OF AMERICA